| Name |
Description |
Page Modified |
| Pharmacokinetic/Pharmacodynamic Analysis of Data from a Phase III Trial of Linezolid IV/PO for the Treatment of Resistant Gram-Positive Bacterial Infections in Children |
Presented at the 2003 ASCPT Annual Meeting, Washington, DC |
Fri Nov 02 13:15:24 EDT 2007 |
| Comparison of Laboratory Safety Data from Japanese and Non-Japanese in Linezolid Phase I Studies |
Presented at the 2002 ASCPT Annual Meeting, Atlanta, GA |
Fri Nov 02 13:15:24 EDT 2007 |
| Comparison of Linezolid Pharmacokinetics from Phase I Studies of Japanese and Caucasians |
Presented at the 2002 ASCPT Annual Meeting, Atlanta, GA |
Fri Nov 02 13:15:24 EDT 2007 |
| Population Pharmacokinetics (PK) of Linezolid in Neonates and Young Infants |
Presented at the 2002 ICAAC Annual Meeting, San Diego, CA |
Fri Nov 02 13:15:24 EDT 2007 |
| The Role of Population PK/PD Analysis During the Implementation of a Bridging Strategy for Linezolid |
Presented at the 2000 DIA Annual meeting, Hong Kong |
Fri Nov 02 13:15:24 EDT 2007 |
| Internet Based Communication Strategies to Support Linezolid Bridging Programs During Global Drug Development |
Presented at the 2000 DIA Annual Meeting, Hong Kong |
Fri Nov 02 13:15:24 EDT 2007 |
| Population Pharmacodynamic Assessment of Linezolid Efficacy in Community Acquired Pneumonia, Skin and Soft Tissue Infections, and Bacteremia |
Presented at the 2000 ICAAC Annual Meeting, Toronto, Ontario |
Mon Nov 05 15:04:41 EST 2007 |